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Obesity, hypertension, and diabetes are independently associated with cardiac remodeling
and frequently co-cluster. The conjoint and separate influences of these conditions on car-
diac remodeling have not been investigated.
Materials and methods
We evaluated 5,741 Framingham Study participants (mean age 50 years, 55% women)
who underwent echocardiographic measurements of left ventricular (LV) mass (LVM), LV
ejection fraction (LVEF), global longitudinal strain (GLS), mitral E/e’, left atrial end-systolic
(peak) dimension (LASD) and emptying fraction (LAEF). We used multivariable generalized
linear models to estimate the adjusted-least square means of these measures according to
cross-classified categories of body mass index (BMI; normal, overweight and obese), hyper-
tension (yes/no), and diabetes (yes/no).
Results
We observed statistically significant interactions of BMI category, hypertension, and diabe-
tes with LVM, LVEF, GLS, and LAEF (p for all 3-way interactions <0.01). Overweight and
obesity (compared to normal BMI), hypertension, and diabetes status were individually and
conjointly associated with higher LVM and worse GLS (p<0.01 for all). We observed an
increase of 34% for LVM and of 9% for GLS between individuals with a normal BMI and
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without hypertension or diabetes compared to obese individuals with hypertension and dia-
betes. Presence of hypertension was associated with higher LVEF, whereas people with
diabetes had lower LVEF.
Conclusions
Obesity, hypertension, and diabetes interact synergistically to influence cardiac remodeling.
These findings may explain the markedly heightened risk of heart failure and cardiovascular
disease when these factors co-cluster.
Introduction
Obesity, diabetes mellitus, and arterial hypertension are important independent risk factors
for heart failure [1–3]. Accordingly, distinct forms of obesity cardiomyopathy [4–8], diabetic
cardiomyopathy [9–13], and hypertensive heart disease [14–17] have been well described.
Obesity increases cardiac output by increasing central and total blood volume and lowering
peripheral resistance [4–6]. These hemodynamic changes are accompanied by an increase in
left ventricular (LV) wall stress, leading to LV diastolic dysfunction and hypertrophy (LVH),
and left atrial (LA) enlargement [4–6]. Additionally, metabolic and neurohormonal changes in
obesity (e.g., increased levels of myocardial triglycerides and fatty acids) may lead to subclini-
cal myocardial dysfunction, reflected by an impairment of LV strain-based measurements [5–
7], while LV ejection fraction (LVEF) is preserved [4, 5].
The metabolic changes seen in diabetes (such as hyperinsulinemia and hyperglycemia) alter
myocardial metabolism and promote myocardial inflammation, fibrosis, and cardiac remodel-
ing [9–12]. Whereas LVEF is often preserved in diabetes, the altered metabolic milieu can con-
tribute to chamber remodeling, LV hypertrophy and diastolic dysfunction, and subtle
impairment of myocardial systolic function [9, 11, 12].
Myocardial hypertrophy occurs as a compensatory mechanism to pressure overload in
hypertension [15–17]. Myocyte hypertrophy is associated with interstitial fibrosis, changes in
cardiomyocyte metabolism, myocyte apoptosis, and microvascular dysfunction. These myo-
cardial changes in hypertension manifest as pathological LV and LA remodeling accompanied
by diastolic dysfunction, LVH, and subtle myocardial systolic dysfunction, while LVEF is ini-
tially preserved [14–17]. Thus, obesity, diabetes mellitus and arterial hypertension all cause
LVH, but it is yet unclear how their conjoint presence may influence cardiac structure, func-
tion and chamber geometry [4–6, 8, 9, 13, 14, 18–27].
Obesity, diabetes, and hypertension often coexist and presumably their conjoint presence
may be associated with an adverse impact on cardiac structural and functional remodeling.
Prior investigations have evaluated the effects of presence of these conditions in pair-wise
combinations and reported that presence of any two of these conditions seems to be additively
associated with adverse cardiac remodeling [28–37], worse LV diastolic function [28, 29, 31,
37], and an impairment of LV strain-based measures [38–40] and LV long axis function [28],
whereas LVEF is preserved typically [28, 29, 35]. These previous investigations did not analyze
the joint effects when all three conditions are present concomitantly [28–36, 39, 40], were
mostly conducted in smaller samples [28, 29, 32–35, 37–39], and only a few studies investi-
gated their possible interactions [28, 35, 36].
In the present investigation, we compared the independent and conjoint associations of
obesity, diabetes mellitus, and arterial hypertension with a comprehensive panel of
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echocardiographic measures including measures of LV size and geometry, LV systolic and dia-
stolic function, LA size and function. We hypothesized that obesity, diabetes, and hypertension
interact synergistically (rather than additively) measured by interaction terms to influence car-
diac remodeling in the community.
Materials and methods
Study sample
The design and selection criteria for the Framingham Heart Study (FHS) Offspring Study, the
Third Generation Cohort and the minority Omni Cohort 1 have been described elsewhere
[41–43]. The present investigation included participants from the FHS Offspring cohort who
attended their eighth examination cycle (N = 3021; 2005–08), the FHS Omni 1 cohort who
attended their third examination cycle (N = 298; 2005–08), and the FHS Third Generation
Cohort who attend their first examination cycle (N = 4095; 2002–05). The study protocol was
approved by the Institutional Review Board of the Boston University Medical Center and all
study participants provided written informed consent.
The analytic methods, data, and study materials will not be made available to other
researchers for purposes of reproducing the results or replicating the procedure.
There were, 7,414 eligible participants from the three cohorts. We excluded 93 individuals
with prevalent heart failure and 1580 individuals due to missing data (see S1 Fig), resulting in
a final sample of 5741 participants.
Measurements of covariates
During their FHS examinations, participants provided a detailed medical history, and under-
went phlebotomy (after an overnight fast) for the assessment of CVD risk factors including a
standard lipid panel and renal function, and a cardiovascular-targeted physical examination
that included standardized anthropometry and blood pressure measurements. The presence of
arterial hypertension was defined as a systolic blood pressure�140mm Hg or a diastolic blood
pressure�90 mm Hg or the current use of antihypertensive medications. We classified partici-
pants as having diabetes mellitus if they had a fasting blood glucose concentration�126 mg/
dL or if they were treated with any hypoglycemic medication. The presence of normal, over-
weight and obesity was defined based on the participant’s body mass index (BMI; normal:
BMI<25kg/m2, overweight: 25kg/m2�BMI<30kg/m2, obese: BMI�30kg/m2).
Current smoking was defined as having smoked cigarettes regularly during the year ante-
dating the FHS examination. Details of methods and criteria of measurement of all covariates
have been published previously [44].
Measurement of echocardiographic variables
All attendees underwent routine transthoracic echocardiography based on a standardized pro-
tocol on an HP Sonos 5500 ultrasound machine (Phillips Medical Systems, Andover, MA).
Based on the recommendations of the American Society of Echocardiography (ASE), digitized
images were obtained and measured offline. Digital images were used to measure LV end-sys-
tolic (LVSD) and end-diastolic (LVDD) dimensions as well as left atrial end-systolic (peak)
dimension (LASD) and left atrial end-diastolic dimension (LADD). End-diastolic thicknesses
of the LV posterior wall and the LV septum were summated to yield LV wall thickness
(LVWT) [45]. Relative wall thickness (RWT) was calculated as equal to (LVWT)/LVDD) [46].
We estimated LV mass (LVM) using the method by Devereux et al, as follows: LVM = (0.8�
(1.04(LVDD + septal wall thickness + posterior wall thickness)3 –LVDD3)+0.6) [47]. Because
PLOS ONE Influences of comorbidities on cardiac remodeling
PLOS ONE | https://doi.org/10.1371/journal.pone.0243199 December 10, 2020 3 / 19
LVM indexed to body surface area (LVMIBSA) is used to classify LV geometry, but such index-
ation may underestimate LVH in obese individuals, we indexed LVM to height (LVMIheight)
and to height ^2,7 (LVMIheight^2.7) additionally [36, 46].
We defined LV geometry thus: Normal LV geometry as LVMIBSA� 95 g/m
2 in women or
LVMIBSA� 115 g/m
2 in men and RWT� 0.42. Concentric remodeling was defined as
LVMIBSA� 95 g/m
2 in women or LVMIBSA� 115 g/m
2 in men and RWT > 0.42. LVH was
defined as LVMIBSA > 95 g/m
2 in women or LVMIBSA > 115 g/m
2 in men. In the presence of
LVH, eccentric LVH was defined as RWT� 0.42 and concentric LVH as RWT > 0.42 [46].
LVEF was calculated based on the Teichholz formula [48], which closely approximates that
estimated by quantitative two-dimensional methods in the FHS laboratory [49]. We measured
mitral annular plane systolic excursion (MAPSE), as recommended [50], by measuring the sys-
tolic excursion of the mitral annulus from its lowest point at end-diastole to its highest point at
the time of aortic valve closure at the lateral side of the mitral valve annulus in the apical four-
chamber view.
The speckle-tracking analyses of LV function was performed using an offline analysis pro-
gram (2D Cardiac Performance Analysis version 1.1, TomTec Imaging Systems GmbH,
Unterschleißheim, Germany) according to a standardized protocol that has been described in
detail previously [51]. In summary, global longitudinal strain (GLS) was assessed in the apical
two and apical four chamber views, and global circumferential strain (GCS) was assessed in
the short axis view.
For the measurement of LV diastolic function, we derived early transmitral flow velocity
(E), and the early systolic mitral annulus velocity (E’, using tissue Doppler imaging at the lat-
eral mitral annulus) to calculate the E/e’ ratio [52].
We obtained maximum and minimum volumetric measurements of the LA (LAmax and
LAmin) from apical two and four-chamber views in offline analysis of digital images using the
recommended Simpson’s biplane summation of disks method on a Digisonics DigiView Sys-
tem Software (ver. 3.7.9.3, Digisonics, Houston, TX). We calculated left atrial emptying frac-
tion (LAEF) as ([LAmax—LAmin]/LAmax)�100 as previously published [46, 53]. LAmax and
LAmin measurements were not available for the Third Generation Cohort, but left atrial frac-
tional shortening (LAFS) was available for all participants (LAFS was calculated as [LAS-
D-LADD]/LASD�100). Therefore, we used a linear regression model for the Offspring cohort,
adjusting age, smoking, BMI, diabetes, systolic blood pressure, diastolic blood pressure, anti-
hypertensive medication, heart rate, creatinine, high-density lipoprotein, low-density lipopro-
tein, and log(triglycerides), stratified by sex, with LAEF as the dependent variable, and LAFS,
LAFS squared, and LAFS cubed as independent variables. Based on the resulting regression
equations, we imputed LAEF values for all cohorts.
Measurements of the echocardiographic variables evaluated in this investigation are sum-
marized and depicted in Fig 1. Data on inter-observer correlations have been previously pub-
lished [51, 53, 54].
Statistical analyses
We assessed baseline characteristics for the entire study sample and separately for each BMI
category. We used natural-logarithm transforms of E/e’, LASD, LVM, LVMI-BSA, LVMI-
height, LVEF, LVWT, and RWT in order to normalize their skewed distributions.
There were twelve strata when the three BMI categories were cross-classified by diabetes
(yes/no) and hypertension (yes/no) status. Using multivariable generalized linear models, we
estimated least square means of LVM, LASD, LVEF, GLS, E/e’, and LAEF (dependent vari-
ables) according to BMI category (normal, overweight and obese), hypertension (yes/no)
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status, and diabetes (yes/no) status (independent exposure variables) separately and jointly. All
models were adjusted for age, sex, and cohort status. We used a Bonferroni-corrected p value
<0.003 (= 0.05/(3�6)) because we investigated 6 echocardiographic variables in relation to 3
different groups. We incorporated cross-product interaction terms for BMI category, hyper-
tension status, and diabetes status to examine potential effect modification of associations
(with the dependent variables) of each exposure individually by the conjoint presence of the
other exposures. For the interaction terms, we used a p-value threshold of p<0.05 to indicate
statistical significance.
We generated frequencies of normal LV geometry, concentric remodeling, eccentric LVH,
and concentric LVH by BMI category, hypertension and diabetes status groupings.
In secondary analyses, we used regression models to estimate least square means of
LVMIBSA, LVMIheight, LVMIheight^2.7, LVWT, RWT, MAPSE, and GCS as additional measures
of cardiac mass, wall thickness, and LV systolic and diastolic function, respectively. A less con-
servative p-value threshold of<0.05 was used for these exploratory analyses.
Fig 1. Schematic presentation of the measurement of the investigated echocardiographic measures. Panel A shows
a 2D parasternal long axis view, lines B and C indicate the position of the m-mode. The respective m-mode view is
shown in panels B and C. Left ventricular end-diastolic dimension (LVDD) and left ventricular end-systolic
dimension (LVSD), posterior wall thickness, and septal wall thickness are measured as shown in panel B. Left
ventricular mass (LVM), relative wall thickness (RWT) and left ventricular ejection fraction (LVEF) are calculated
based on these measures. Left atrial end-systolic dimension (LASD) and left atrial end-diastolic dimension (LADD) are
measured as shown in panel C. Panel E depicts the basic directions in which circumferential strain (CS) and
longitudinal strain (LS) are measured. Panel F shows the measurements of transmitral Doppler (E and A) and tissue
Doppler (e’ and a’) velocities. We have measured early systolic mitral annulus velocity using tissue Doppler imaging at
the lateral mitral annulus. E/e’ ratio is calculated based on these measurements. Mitral annular plane systolic excursion
(MAPSE) was measured by the systolic excursion of the mitral annulus from its lowest point at end-diastole (panel G,
right) to its highest point at the time of aortic valve closure (panel G, left) at the lateral side of the mitral valve annulus
in the apical four-chamber view. Maximum and minimum volumetric measurements of the LA (LAmax and LAmin)
from apical two and four-chamber views were taken at end-diastole for LAmin (panel H, left) and at end-systole for
LAmax (panel H, right). Left atrial emptying fraction (LAEF) is calculated based on these measurements.
https://doi.org/10.1371/journal.pone.0243199.g001
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We calculated variance inflation factor values for all models, but we did not observe major
collinearity. All analyses were performed using SAS version 9.4 (SAS, Cary, NC).
Results
Baseline characteristics
The clinical characteristics of our middle-aged sample (mean age 50 years, 54.6% women) are
presented in Table 1. About 38% of the participants were overweight and 23% were obese,
Table 1. Baseline characteristics of study sample, stratified by BMI category.
Overall (n = 5741) Normal weight (n = 2229) Overweight (n = 2186) Obese (n = 1326)
Cardiovascular risk factors
Age, years 50 (15) 47 (15) 51 (15) 52 (14)
Female, % 54.6 69.7 41.4 51.1
Height, cm 169.1 (9.6) 167.7 (9.1) 170.7 (9.7) 168.9 (9.7)
Weight, kg 77 (17) 63 (9) 80 (10) 98 (15)
Body mass index, kg/m2 27.0 (5.1) 22.4 (1.8) 27.3 (1.4) 34.1 (4.0)
Systolic blood pressure, mm Hg 121 (16) 115 (16) 123 (16) 125 (15)
Diastolic blood pressure, mm HG 74 (10) 72 (9) 76 (9) 77 (10)
Heart rate, bpm 59 (9) 59 (9) 59 (9) 61 (9)
No Smoking, % 70 67 71 72
Active Smoking, % 17 18 17 16
Former Smoking, % 14 15 12 13
Hypertension treatment, % 22 12 24 35
Prevalent CVD, % 5 3 6 8
Serum creatinine, mg/100ml 0.84 (0.22) 0.79 (0.16) 0.87 (0.23) 0.84 (0.26)
Total cholesterol, mg/100ml 188 (35) 185 (34) 191 (36) 190 (36)
High density lipoprotein, mg/100ml 56 (17) 63 (18) 53 (15) 50 (14)
Low density lipoprotein, mg/100ml 110 (32) 104 (31) 114 (32) 113 (32)
Triglycerides, mg/100ml 109 (58) 87 (45) 116 (60) 132 (63)
Category
No hypertension, no diabetes, N (%) 3936 (68.6%) 1838 (82.5%) 1436 (65.7%) 662 (49.9%)
Hypertension, no diabetes, N (%) 1496 (26.1%) 346 (15.5%) 645 (29.5%) 505 (38.1%)
Diabetes, no hypertension N (%) 85 (1.5%) 17 (0.8%) 30 (1.4%) 38 (2.9%)
Hypertension and diabetes, N (%) 224 (3.9%) 28 (1.3%) 75 (3.4%) 121 (9.1%)
Echocardiographic indices
Left ventricular mass, g 161.1 (44.1) 139.2 (35.1) 170.2 (42.3) 182.8 (44.5)
Left ventricular mass indexed by height, g/m 94.7 (23.3) 82.6 (18.2) 99.2 (22.0) 107.7 (23.4)
Left ventricular mass indexed by body surface area, g/m2 84.2 (17.5) 80.8 (16.0) 87.0 (18.2) 85.3 (17.7)
Left ventricular wall thickness, cm 1.84 (0.26) 1.72 (0.22) 1.89 (0.24) 1.97 (0.26)
Relative wall thickness 0.38 (0.05) 0.36 (0.05) 0.38 (0.05) 0.39 (0.06)
Left atrial systolic dimension, cm 3.77 (0.51) 3.48 (0.42) 3.87 (0.45) 4.09 (0.47)
Left ventricular ejection fraction, % 66 (6) 66 (6) 66 (6) 66 (6)
Mitral annular plane systolic excursion, cm 1.57 (0.23) 1.57 (0.22) 1.57 (0.23) 1.57 (0.23)
Global longitudinal strain, % -20.3 (3.1) -21.1 (3.1) -19.9 (2.9) -19.5 (3.2)
Global circumferential strain, % -29.8 (5.3) -29.6 (5.4) -29.8 (5.2) -30.0 (5.2)
E/e’ 6.3 (1.9) 5.9 (1.7) 6.3 (1.9) 6.9 (2.0)
Left atrial emptying fraction, % 48.1 (2.1) 48.3 (2.0) 48.0 (2.1) 47.9 (2.2)
Data are shown as means (standard deviation) for continuous variables and as percentage for categorical variables. Prevalent CVD = prevalent cardiovascular disease.
https://doi.org/10.1371/journal.pone.0243199.t001
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26% had hypertension but no diabetes, 2% had diabetes but no hypertension, and 4% had both
hypertension and diabetes. In about 3% of the individuals, diabetes, hypertension and over-
weight/obesity co-clustered. Most participants with hypertension or diabetes were overweight
or obese.
Association of body mass index, hypertension, and diabetes with cardiac
structural remodeling
When modeled individually, overweight/obese participants and individuals with hypertension
or diabetes had higher LVM, higher LASD (Table 2), and, in secondary analysis, higher
LVMIheight, LVMIheight^2.7, LVWT, and RWT compared to those with normal body mass
index, and participants without hypertension or diabetes, respectively (S1 Table). Individuals
with either hypertension or diabetes had higher LVMIBSA compared to individuals without
hypertension or diabetes, but LVMIBSA did not differ between normal weight, overweight and
obese individuals.
When we included BMI category, hypertension and diabetes status jointly in a model, we
observed significant three-way multiplicative statistical interactions for LVM, and, in second-
ary analysis, for LVMIheight, LVMIheight^2.7, LVMIBSA, LVWT, and RWT (Table 3, S2 Table).
We observed a pattern of increasing LVM values across the three BMI categories, for all
combinations of hypertension and diabetes status. The increase in LVM between those with
normal BMI and obese individuals was most pronounced among individuals with diabetes
Table 2. Least square means of echocardiographic parameters by BMI category, hypertension status, and diabetes
status (modeled separately), adjusted for age, sex, and cohort.
Trait A) BMI Category






LVM, g 142.6 157.8 174.7 <0.0001
LASD, cm 3.53 3.78 4.03 <0.0001
LVEF, % 65.64 65.60 65.75 0.73
GLS, % -20.9 -20.1 -19.5 <0.0001
E/e’ 5.71 6.07 6.56 <0.0001
LAEF, % 48.1 48.0 48.0 0.20
Trait B) Hypertension Status C) Diabetes Status
No HTN (70%) HTN (30%) P Value No DM
(95%)
DM (5%) P Value
LVM, g 151.0 166.0 <0.0001 154.5 169.9 <0.0001
LASD, cm 3.69 3.86 <0.0001 3.72 3.96 <0.0001
LVEF, % 65.36 66.34 <0.0001 65.70 64.84 0.0087
GLS, % -20.5 -19.7 <0.0001 -20.3 -19.5 <0.0001
E/e’ 5.86 6.46 <0.0001 6.00 6.76 <0.0001
LAEF, % 48.1 47.9 0.0005 48.1 47.3 <0.0001
Least squares means of left ventricular mass (LVM), left atrial systolic dimension (LASD), left ventricular ejection
fraction (LVEF), global longitudinal strain (GLS), E/e’, and left atrial emptying fraction (LAEF) according to A) body
mass index (BMI) category (normal weight: BMI < 25kg/m2, overweight: 25kg/m2� BMI < 30kg/m2, obese:
BMI� 30kg/m2), B) hypertension status (HTN), C) and diabetes status (DM). All models are adjusted for cohort,
age, and sex. We used a Bonferroni-corrected p<0.003 (= 0.05/(3�6)) because we investigated 6 echocardiographic
variables in relation to 3 different groups.
https://doi.org/10.1371/journal.pone.0243199.t002
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(37% increase) and with both diabetes and hypertension (33% increase) (Fig 2A). Within each
BMI category, hypertension was associated with a similar increase of LVM of ~6%, while the
increase in LVM seen in individuals with diabetes was more pronounced in obese (15%) versus
in individuals with normal BMI (1%). We observed similar patterns in secondary analyses for
LVMIheight, LVMIheight^2.7, LVWT and RWT (S1A, S1C and S1D Fig). In contrast, there was
no increase of LVMIBSA with BMI category (S1B Fig).
Similar to LVM, LASD increased from normal BMI to overweight and to obese individuals
for all combinations of diabetes and hypertension, with the strongest increase among those
with diabetes (20%) (Fig 2B), but a three-way interaction term was statistically nonsignificant
(consistent with additive effects).
Association of body mass index, hypertension, and diabetes with cardiac
function
When analyzed separately, overweight/obese participants and those with hypertension or dia-
betes had higher (presumably unfavorable) values of GLS and E/e’ compared to those with
normal body mass index, and those without hypertension or diabetes, respectively (Table 2).
Individuals with hypertension or diabetes had lower values of LAEF compared with individu-
als without hypertension or diabetes, respectively. There was no difference in LAEF across the
three BMI categories.
Individuals with hypertension had higher LVEF and, in secondary analysis, lower (more
negative) GCS values (both presumably favorable effects) compared to individuals without
hypertension. In contrast, individuals with diabetes had higher (less negative values) GCS
Table 3. Least square means of echocardiographic traits by BMI category, hypertension status, and diabetes status (modeled jointly), adjusted for age, sex, and
cohort.
Echo Parameter BMI Category Healthy DM, no HTN HTN, no DM HTN and DM P-Value for 3-way interaction
LVM (g) Normal 140.7 141.5 150.7 140.7 0.0042
Overweight 155.1 160.4 163.2 169.7
Obese 168.6 193.5 179.8 187.3
LASD, cm Normal 3.51 3.50 3.60 3.69 0.31
Overweight 3.76 3.79 3.82 3.97
Obese 3.98 4.21 4.06 4.18
LVEF, % Normal 65.43 65.76 66.84 61.96 0.0002
Overweight 65.35 66.26 66.36 64.21
Obese 65.34 63.16 66.40 66.46
GLS, % Normal -21.1 -17.7 -20.3 -20.7 0.0005
Overweight -20.2 -19.3 -19.7 -19.1
Obese -19.7 -19.3 -19.1 -19.2
E/e’ Normal 5.60 5.77 6.09 6.41 0.25
Overweight 5.92 6.22 6.39 6.91
Obese 6.36 7.30 6.68 7.23
LAEF, % Normal 48.1 47.1 48.0 48.5 0.0006
Overweight 48.1 47.6 47.9 46.8
Obese 48.2 46.6 47.8 47.6
Least squares means of left ventricular mass (LVM), left atrial systolic dimension (LASD), left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), E/e’,
and left atrial emptying fraction (LAEF) according to body mass index (BMI) category (normal weight: BMI < 25kg/m2, overweight: 25kg/m2� BMI < 30kg/m2, obese:
BMI� 30kg/m2), hypertension status (HTN), and diabetes status (DM). All models are adjusted for cohort, age, and sex.
P-Value <0.05 was considered significant for interaction terms.
https://doi.org/10.1371/journal.pone.0243199.t003
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values (S1 Table) compared to individuals without diabetes. Higher BMI was accompanied by
an increase in MAPSE in secondary analysis (presumably a favorable effect) whereas individu-
als with hypertension or diabetes had lower MAPSE (S1 Table). We observed statistically sig-
nificant three-way interactions between BMI categories, hypertension, and diabetes status for
LVEF, GLS, and LAEF (Table 3) in the joint models.
LVEF (Fig 2C) was higher in normal weight, overweight, and obese individuals with hyper-
tension compared to normal weight, overweight, and obese individuals without hypertension
(+2% increment in LVEF for all three groups). Normal and overweight individuals with diabe-
tes had higher LVEF compared to normal and overweight individuals without diabetes (+1%
increment in LVEF). Obese individuals with hypertension and diabetes had higher LVEF than
individuals with a normal BMI who had hypertension and diabetes (+7% increment in LVEF).
In contrast, LVEF was lower in obese individuals with diabetes compared to their normal BMI
counterparts (4% decrement in LVEF).
GLS (Fig 2D, GLS is depicted as -GLS) values were higher (less negative, i.e., presumably
unfavorable effects) in individuals with diabetes and/or hypertension in all BMI categories
(+2% to +16% increase) and in overweight or obese individuals compared to individuals with
normal BMI in individuals with hypertension or those with hypertension and diabetes (+6%
to +7% increase, respectively).
Fig 2. Means of echocardiographic measures. Least squares means of left ventricular mass (A), left atrial systolic
dimension (B), left ventricular ejection fraction (C), negative global longitudinal strain (D), E/e’ (E), and left atrial
emptying fraction (F) according to cross-classified body mass index (normal weight: BMI< 25kg/m2, overweight:
25kg/m2� BMI< 30kg/m2, obese: BMI� 30kg/m2)) hypertension, and diabetes status categories. All models are
adjusted for cohort, age and sex. P values correspond to 3-way interactions.
https://doi.org/10.1371/journal.pone.0243199.g002
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We investigated MAPSE and GCS (S2E and S2F Fig, GCS is depicted as -GCS) as addi-
tional measures of LV long axis and circumferential function in secondary analyses. MAPSE
was lower in individuals with diabetes and/or hypertension in all BMI categories (0 to -3% dec-
rement) compared to individuals without diabetes and/or hypertension. However, MAPSE
was higher in obese individuals compared to that in individuals with normal BMI irrespective
of their diabetes or hypertension status (2% to 3% increment).
GCS values were higher (less negative, i.e., presumably unfavorable) in obese individuals
compared to individuals with normal BMI with diabetes and/or hypertension (1% to 2%
worse) and in overweight participants with diabetes and hypertension compared to their coun-
terparts with normal BMI (5% worse). In contrast, GCS values were lower (more negative, i.e.,
presumably beneficial) in individuals with hypertension compared to individuals without
hypertension in all three BMI categories (-2% to -3% lower/better).
E/e’ (Fig 2E) was 3% higher in participants with normal BMI with diabetes compared to
participants with normal BMI without diabetes, and it was 15% higher in obese subjects with
diabetes compared to obese subjects without diabetes. Individuals with hypertension had
5–8% higher E/e’ than normotensive individuals in all BMI categories, and individuals with
both diabetes and hypertension had 14–17% higher E/e’ than individuals without either condi-
tion (in all BMI groups). The highest increase in E/e’ was observed in obese individuals with
diabetes (27% increase relative to those with normal BMI).
While there were no differences in LAEF between individuals with normal BMI, overweight
or obesity (Fig 2F), individuals with hypertension and/or diabetes had lower adjusted mean
values of LAEF compared to individuals without hypertension and/or diabetes. We observed
the lowest values of LAEF in obese participants with diabetes but without hypertension, and in
overweight participants with diabetes and hypertension.
Association of body mass index, hypertension, and diabetes with LV
geometric patterns
The prevalence of normal LV geometry decreased and that of concentric remodeling, eccentric
LVH, and concentric LVH increased among those with hypertension and/or diabetes regard-
less of their BMI category (Fig 3, S3 Table). Only about 50% of subjects with both hyperten-
sion and diabetes had normal LV geometry. Overweight and obesity were associated with an
increase in concentric remodeling in individuals without hypertension or diabetes. With
increasing BMI, there were only small changes in the prevalence of LV geometric patterns in
individuals with hypertension. In the presence of diabetes, the presence of overweight and obe-
sity shifted the distribution of LV geometry to higher frequencies of concentric remodeling
and concentric LVH (relative to those without diabetes). In participants with both diabetes
and hypertension, overweight and obesity led to only a small change of the frequency of abnor-
mal geometry generally but increased the frequency of concentric LVH.
Discussion
We investigated conjoint influences of obesity, hypertension, and diabetes on cardiac structure
and function, and chamber geometry in a large community-based sample free of heart failure.
Principal findings
Our principal findings are four-fold, as summarized in Table 4.
First, we observed that BMI category, hypertension, and diabetes were each associated with
cardiac remodeling and altered LV geometry. Most of these associations reflected unfavorable
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consequences, although we observed associations between hypertension and higher LVEF and
better GCS, and between higher BMI and greater MAPSE (see below).
Second, when modeled jointly, we observed significant three-way statistical interactions
between BMI category, hypertension, and diabetes for LVM, LVEF, GLS, and LAEF; and in
Fig 3. Distribution of left ventricular geometry. Frequencies (percentages) of left ventricular geometry (LV) patterns
by body mass index (BMI) category (normal weight: BMI< 25kg/m2, overweight: 25kg/m2� BMI< 30kg/m2, obese:
BMI� 30kg/m2), hypertension status, and diabetes status.
https://doi.org/10.1371/journal.pone.0243199.g003
Table 4. Summary of associations.
Three-way interaction + Additive effects
LVM LVEF LAEF GLS LASD E/e’ MAPSE GCS
Hypertension " " # " " " # "
Obesity " ! ! " " " " !
Diabetes " " # " " " # #
" indicates values increase (become more positive/less negative in case of GLS and GCS)
! indicates no association
# indicates values decrease (become less positive/more negative in case of GLS and GCS)
https://doi.org/10.1371/journal.pone.0243199.t004
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secondary analyses, for LVMI, LVWT, and RWT. The strengths of the unfavorable associa-
tions of these three risk factors (overweight/obesity, hypertension and diabetes) with LVM,
GLS, and LAEF suggest that these influences are synergistic. In contrast, for select echocardio-
graphic measures, the associations of these risk factors were opposite in directionality—for
instance, individuals with hypertension tended to have higher LVEF compared to their non-
hypertensive counterparts (BMI being held constant) whereas obese individuals had a lower
LVEF compared to those with a normal BMI (blood pressure being held constant).
Third, there were no statistically significant synergistic interactions for these three risk fac-
tors in relation to their associations with LASD or E/e’ in primary analyses, and for their rela-
tions to MAPSE and GCS in secondary analyses. There were unfavorable additive effects of
BMI, diabetes and hypertension on LASD and E/e’. For select echocardiographic measures the
associations of these three risk factors varied in directionality. For instance, obesity was posi-
tively associated with MAPSE, whereas diabetes or hypertension were negatively related to
long axis LV function. Likewise, hypertension was associated with better (more negative) GCS,
whereas relations for obesity or diabetes were opposite in direction.
Fourth, we observed a lower prevalence of normal LV geometry in obese individuals and in
individuals with hypertension or diabetes; normal LV geometry was least common in partici-
pants with both hypertension and diabetes (Fig 3) suggesting synergistic effects.
Individual associations of body mass index, diabetes and hypertension with
cardiac remodeling
Our findings that a higher BMI category and the presence of hypertension or diabetes each is
associated with adverse LV and LA remodeling have been reviewed extensively in the literature
along with delineation of the underlying mechanisms [4–17]. The observation, that a higher
BMI category was not associated with LVMIBSA but was associated with greater LVM, LVMI-
height and LVMIheight^2.7, underscore previous observations that indexation of LVM by body
surface area may mask the adverse impact of obesity on cardiac mass and hypertrophy [55].
We observed, that adjusted mean values of GCS were more negative (presumably favorable
effects) in subjects with hypertension, but higher (less negative, i.e., unfavorable) in subjects
with diabetes. There is evidence that in the early stages of myocardial response in hypertension,
when GLS may be impaired, GCS is augmented to maintain LVEF [56]. It is possible that the
subtle myocardial dysfunction in our study sample was more pronounced in participants with
diabetes compared to individuals with hypertension, leading to augmented GCS in individuals
with hypertension but worse GLS and GCS in those with diabetes. In our investigation adjusted
mean values of LVEF were higher in individuals with hypertension, which has been described
previously [57, 58]. One possible explanation for the increase in LVEF might be an increase in
ventricular torsion and/or LV wall thickening in individuals with hypertension [58].
Presumably unfavorable associations between diabetes [28] and hypertension [28, 59] with
MAPSE have been described previously [48]. We observed that MAPSE was higher (presum-
ably a favorable effect) in overweight/obese subjects. So far, only unfavorable associations
between MAPSE and body weight have been described by three prior studies with small sam-
ples (n<120) [28, 60, 61], two of which investigated severely obese individuals with a mean
BMI>40kg/m2 [60, 61]. Therefore, previous studies may not be comparable to our present
investigation of a larger community-based sample. A possible explanation for the favorable
association of higher BMI with MAPSE observed in our investigation might be the increase
cardiac work necessitated with higher body weight [4–6]. Additional studies including larger
samples are warranted to confirm our findings and to investigate the physiological mecha-
nisms underlying the observed associations.
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Conjoint associations of body mass index, diabetes and hypertension with
cardiac structural remodeling
Previous investigators have reported additive and unfavorable associations of obesity and
hypertension [30–33], obesity and diabetes [30–32, 37], and hypertension and diabetes [28–30,
37] with measures of cardiac remodeling. Two studies investigated possible interactions
between hypertension and obesity on LVM. A prior study of severely obese individuals
reported an interaction [35], while a previous report from the FHS did not observe any inter-
action between obesity and hypertension in terms of their associations with LVM but that
report excluded participants who were on antihypertensive medications and presumably had
longstanding high blood pressure [36].
We observed significant three-way statistical interactions between BMI category, hyperten-
sion, and diabetes for LVM, LVMI and LVWT, which indicates that BMI, hypertension and
diabetes have interrelated influences on LV remodeling. It is noteworthy that an overweight
individual without diabetes or hypertension already has comparable LVM and LVWT as an
individual with a normal BMI who has both hypertension and diabetes. Although a participant
with hypertension and diabetes is usually considered to be at risk for heart failure, a similar
risk (of heart failure) might be underappreciated in overweight but seemingly healthy individ-
uals. The high values of LVM observed in obese individuals with diabetes emphasizes the
higher risk of heart failure observed in such individuals, thereby might underscore the impor-
tance of weight loss and optimal management of diabetes in obese individuals. In fact, a recent
echocardiographic study of patients with diabetes reported that those with diabetes but with
low rates of hypertension and obesity remained at higher risk of cardiovascular mortality and
hospitalization if they had increased LVMI [37].
Conjoint associations of body mass index, diabetes, and hypertension with
LV diastolic function
A previous study [31] of approximately 2500 participants investigated the associations between
BMI category and several echocardiographic markers including E/e’ and E/A in the presence
or absence of at least one component of the metabolic syndrome (including diabetes and
hypertension). That study reported that obesity was associated with worse LV diastolic
function in both metabolically healthy and unhealthy individuals, and that unhealthy partici-
pants had worse LV diastolic function compared to their counterparts with a normal BMI
[31].
Similarly, we observed an increase in E/e’ with increasing BMI category, with the increase
being more pronounced in obese individuals with diabetes compared to obese individuals
without diabetes. We observed higher values of E/e’ for individuals with normal BMI with
hypertension compared to individuals with normal BMI with diabetes. We did not observe
any statistically significant interaction between BMI category, hypertension and diabetes for E/
e’. Overall, our results suggest that there are additive associations of BMI category, hyperten-
sion and diabetes on LV diastolic function.
Conjoint associations of body mass index, diabetes, and hypertension with
LV systolic function
There are only few reports on the possible conjoint associations of obesity, hypertension, and
diabetes with LVEF [28, 29, 35], GLS [38–40], GCS [38], and MAPSE [28]. These investiga-
tions reported unfavorable associations between different combinations of obesity, hyperten-
sion and diabetes, with GLS, GCS, and MAPSE, but not with LVEF [28, 29, 35, 37–40].
PLOS ONE Influences of comorbidities on cardiac remodeling
PLOS ONE | https://doi.org/10.1371/journal.pone.0243199 December 10, 2020 13 / 19
We observed a significant three-way multiplicative interaction for the associations of BMI
category, hypertension, and diabetes with GLS, which suggests synergistic effects. Individuals
with all three conditions or the combination of obesity with either diabetes or hypertension
had the highest (less negative, i.e., unfavorable) mean adjusted values of GLS.
Hypertension was associated with better (more negative) mean GCS, but this association
was attenuated by the presence of a higher BMI category or diabetes.
Overweight and obesity were associated with higher (favorable) mean MAPSE values com-
pared to normal weight individuals in all subgroups (no additional risk factors, only hyperten-
sive, only diabetes, and both, diabetes and hypertensive), but MAPSE was lower (unfavorable)
in individuals with hypertension, diabetes, or both if BMI was held constant. Overall, these
observations are consistent with a possible greater long axis LV shortening with higher BMI
category, but attenuated shortening in the presence of concomitant hypertension and diabetes
(on MAPSE). As mentioned above, additional studies are warranted to confirm this observa-
tion and to investigate potential physiological mechanisms.”
Conjoint associations of body mass index, diabetes and hypertension with
LAEF
We observed lower adjusted mean values for LAEF in individuals with diabetes or hyperten-
sion compared to individuals without diabetes or hypertension, respectively. However, we did
not observe any statistically significant associations between BMI category and LAEF. The
inverse associations of hypertension and diabetes with LAEF seemed to be synergistic,
although the absolute magnitude of the effect sizes (0–3%) were very modest and their clinical
significance is unclear.
Conjoint associations of body mass index, diabetes and hypertension with
LV geometric patterns
In individuals without diabetes or hypertension, there was an overall low prevalence of abnor-
mal LV geometry—we observed an increase in the prevalence of a concentric remodeling pat-
tern with overweight and obesity (compared to normal BMI). There were relatively more
overweight and obese individuals with eccentric compared to concentric LVH. Both, the pres-
ence of concentric and eccentric LVH have been reported in obese individuals with a tendency
towards a higher prevalence of eccentric LVH. It has been suggested that concomitant hyper-
tension might promote a change in the geometric pattern to concentric LVH [6, 8, 22].
Individuals with hypertension (compared to their non-hypertensive counterparts) had a
relatively higher prevalence of eccentric compared to concentric LVH, irrespective of their
BMI category. The question whether concentric or eccentric LVH is more frequent in individ-
uals with hypertension has been discussed controversially and recent reviews report similar
prevalence of concentric and eccentric LVH or even a slightly higher prevalence of eccentric
LVH in hypertensive individuals. These reports emphasize the role of comorbidities to influ-
ence the pattern of LVH [14, 23].
Previous investigations reported an association between diabetes and abnormal LV geome-
try, but were inconsistent about the relative prevalence of concentric versus eccentric remodel-
ing/LVH [18–20]. We observed that in participants with diabetes and a normal BMI/
overweight, eccentric LVH was the predominant geometric pattern. Yet, in obese individuals
with diabetes the prevalence of concentric LVH was higher. Thus, the BMI category may deter-
mine the pattern of LV geometry in people with diabetes.
Obese individuals with both diabetes and hypertension had a higher prevalence of concen-
tric compared to eccentric LVH. It is possible, that the combination of volume overload
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(obesity), metabolic changes (diabetes, obesity) and pressure overload (hypertension) synergis-
tically contribute to the development of concentric LVH, which is known to most adversely
impact overall survival [21].
Strength and limitations
The strengths of our investigation include the large community-based sample, the evaluation
of a comprehensive panel of novel and standard echocardiographic markers of cardiac remod-
eling and aortic stiffness, and the study of the synergistic interactions between BMI category,
hypertension, and diabetes. However, several limitations of our approach must be considered.
Although we included the racially diverse minority FHS Omni cohort in our sample, our over-
all study sample was comprised predominantly of whites of European ancestry with a low
overall prevalence of diabetes. Future validation of our observations in large multiethnic
cohorts is necessary, especially as the influence of race on LVH has been emphasized [18]. It
must be noted that the mean differences in LVEF across the different strata were small and
within the normal range. Our large sample size might have given us the possibility to detect
very modest differences in echocardiographic measure of LV systolic and LA function that
may be statistically significant, but these small differences might not be clinically meaningful.
Due to the observational as well as cross-sectional design of our investigation, it is not possible
to make causal interferences and we cannot exclude residual confounding by additional factors
not adjusted for.
Conclusions
In our large community-based sample, we observed synergistic interactions between a higher
BMI category and the presence of hypertension or/and diabetes and their associations with
adverse cardiac structural and functional remodeling. Additional studies of larger and multi-
ethnic samples are warranted to confirm our findings and investigate whether these synergistic
effects are also linked to an increased risk of clinical outcomes when these risk factors co-
cluster.
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S1 Fig. Flow diagram representing selection and exclusion process. Abbreviations: CHF:
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ham Offspring Study; Omni 2: Omni 2 Cohort.
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S2 Fig. Least squares means of left ventricular mass indexed by height (A), left ventricular
mass indexed by body surface area (B), left ventricular wall thickness (C), relative wall thick-
ness (D), mitral annular plane systolic excursion (E), and negative global circumferential strain
(F) according to cross-classified body mass index (normal weight: BMI < 25kg/m2, over-
weight: 25kg/m2� BMI< 30kg/m2, obese: BMI� 30kg/m2)) hypertension, and diabetes status
categories. All models are adjusted for cohort, age and sex. P values correspond to 3-way inter-
actions.
(DOCX)
S1 Table. Least square means of echocardiographic traits by BMI category, hypertension
status and diabetes status (modeled separately) in secondary analysis, adjusted for age,
sex, and cohort. Least squares means of left ventricular mass index (LVMI) indexed by height
(g/m), height^2.7, and body surface area (g/m2), left ventricular wall thickness (LVWT), rela-
tive wall thickness (RWT), mitral annular plane systolic excursion (MAPSE), global
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BMI< 25kg/m2, overweight: 25kg/m2� BMI< 30kg/m2, obese: BMI� 30kg/m2), hyperten-
sion status (HTN), and diabetes status (DM). All models are adjusted for cohort, age, sex. Bold
print: p< 0.05, considered significant in secondary analysis.
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S2 Table. Least square means of echocardiographic parameters stratified by BMI category,
hypertension status and diabetes status (modeled jointly) in secondary analysis, adjusted
for age, sex, and cohort. Least squares means of left ventricular mass index (LVMI) indexed
by height, height^2,7, and body surface area, left ventricular wall thickness (LVWT), relative
wall thickness (RWT), mitral annular plane systolic excursion (MAPSE), and global circumfer-
ential strain (GCS) according to body mass index (BMI) category (normal weight: BMI<
25kg/m2, overweight: 25kg/m2� BMI < 30kg/m2, obese: BMI� 30kg/m2), hypertension sta-
tus (HTN), and diabetes status (DM). All models are adjusted for cohort, age, sex. P-Value
<0.05 was considered significant for interaction terms.
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S3 Table. Frequencies of left ventricular geometry category by BMI category, hypertension
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We thank the Framingham Heart Study participants for making this research investigation
possible.
Author Contributions
Conceptualization: Beatrice von Jeinsen, Ramachandran S. Vasan, Vanessa Xanthakis.
Data curation: David D. McManus.
Formal analysis: Ramachandran S. Vasan, Vanessa Xanthakis.
Funding acquisition: Ramachandran S. Vasan, Gary F. Mitchell, Susan Cheng.
Investigation: Beatrice von Jeinsen, Gary F. Mitchell, Vanessa Xanthakis.
Validation: David D. McManus, Susan Cheng, Vanessa Xanthakis.
Visualization: Susan Cheng, Vanessa Xanthakis.
Writing – original draft: Beatrice von Jeinsen, Ramachandran S. Vasan, Vanessa Xanthakis.
Writing – review & editing: Ramachandran S. Vasan, David D. McManus, Gary F. Mitchell,
Susan Cheng, Vanessa Xanthakis.
References
1. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: The Framingham
study. Am J Cardiol. 1974; 34(1):29–34. https://doi.org/10.1016/0002-9149(74)90089-7 PMID:
4835750
PLOS ONE Influences of comorbidities on cardiac remodeling
PLOS ONE | https://doi.org/10.1371/journal.pone.0243199 December 10, 2020 16 / 19
2. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the develop-
ment of congestive heart failure. N Engl J Med. 1972; 287(16):781–7. https://doi.org/10.1056/
NEJM197210192871601 PMID: 4262573
3. Kenchaiah S, Evans J, Levy D, Wilson PWF, Benjamin EJ, Larson MG, et al. Obesity and the Risk of
Heart Failure. N Engl J Med. 2002; 347(5):305–13. https://doi.org/10.1056/NEJMoa020245 PMID:
12151467
4. Aurigemma GP, De Simone G, Fitzgibbons TP. Cardiac remodeling in obesity. Circ Cardiovasc Imag-
ing. 2013; 6(1):142–52. https://doi.org/10.1161/CIRCIMAGING.111.964627 PMID: 23322729
5. Mahajan R, Lau DH, Sanders P. Impact of obesity on cardiac metabolism, fibrosis, and function. Trends
Cardiovasc Med. 2015; 25(2):119–26. https://doi.org/10.1016/j.tcm.2014.09.005 PMID: 25446049
6. Alpert MA, Lavie CJ, Agrawal H, Aggarwal KB, Kumar SA. Obesity and heart failure: epidemiology,
pathophysiology, clinical manifestations, and management. Transl Res. 2014; 164(4):345–56. https://
doi.org/10.1016/j.trsl.2014.04.010 PMID: 24814682
7. Kindel TL, Strande JL. Bariatric surgery as a treatment for heart failure: review of the literature and
potential mechanisms. Surg Obes Relat Dis. 2018; 14(1):117–22. https://doi.org/10.1016/j.soard.2017.
09.534 PMID: 29108893
8. Alpert MA, Lavie CJ, Agrawal H, Kumar A, Kumar SA. Cardiac Effects of Obesity. J Cardiopulm Rehabil
Prev. 2016; 36:1–11. https://doi.org/10.1097/HCR.0000000000000147 PMID: 26629864
9. Lorenzo-Almoros A, Tuñón J, Orejas M, Cortés M, Egido J, Lorenzo Ó. Diagnostic approaches for dia-
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